杜晓利, 陈慧慧, 叶向阳, 谢恬, 何兴瑞. 以RNA为靶标的小分子药物的研究进展J. 药学学报, 2022, 57(10): 2902-2913. DOI: 10.16438/j.0513-4870.2022-0430
引用本文: 杜晓利, 陈慧慧, 叶向阳, 谢恬, 何兴瑞. 以RNA为靶标的小分子药物的研究进展J. 药学学报, 2022, 57(10): 2902-2913. DOI: 10.16438/j.0513-4870.2022-0430
DU Xiao-li, CHEN Hui-hui, YE Xiang-yang, XIE Tian, HE Xing-rui. Research progress of small molecular drugs targeting RNAJ. Acta Pharmaceutica Sinica, 2022, 57(10): 2902-2913. DOI: 10.16438/j.0513-4870.2022-0430
Citation: DU Xiao-li, CHEN Hui-hui, YE Xiang-yang, XIE Tian, HE Xing-rui. Research progress of small molecular drugs targeting RNAJ. Acta Pharmaceutica Sinica, 2022, 57(10): 2902-2913. DOI: 10.16438/j.0513-4870.2022-0430

以RNA为靶标的小分子药物的研究进展

Research progress of small molecular drugs targeting RNA

  • 摘要: 目前临床上所使用的小分子药物大部分以蛋白为靶标, 小分子药物通过与靶标蛋白上的特定位点结合而发挥药效。然而可成药的蛋白在总蛋白数中占据较少部分。“不可成药”蛋白占人体总蛋白的80%。因为大部分的蛋白并没有合适的药物结合位点。在中心法则中, RNA处于蛋白质的上游, 控制着蛋白质的翻译, 靶向RNA的小分子药物研究在一定程度上可以解决蛋白“不可成药”的难题。本综述文章总结了近年来靶向RNA小分子药物研究领域的代表性研究成果, 以及靶向RNA小分子药物的筛选方法, 并着重分析了靶向新冠病毒RNA的小分子药物的最新进展。

     

    Abstract: At present, majority of the small molecular drugs used in clinics target proteins, they exert the efficacy through the binding to specific sites on the target protein. However, the "druggable" protein targets account for a small portion of the total number of proteins, and "non-druggable" proteins account for 80%, because of not having suitable drug binding sites. In the central rule, RNA is located in the upstream of proteins and controls the transcription of proteins. The research of small molecule drugs targeting RNA can solve the problem of protein "undruggable proteins" in some extent. This review summarizes the representative research achievements of small molecular drugs targeting RNA in recent years, and the screening methods applied to this field, with the focuses on the latest progress of small molecular drugs targeting novel coronavirus RNA.

     

/

返回文章
返回